Imatinib is approved by the US FDA for the treatment of chronic myeloid leukemia (CML) and targets the phosphorylation of RTKs including PDGFR-b and v-Kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog (c-KIT) [57]. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.